Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis

Overview of attention for article published in Ophthalmology, August 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 13 news outlets
policy: 1 policy source

twitter: 1 X user
guideline: 1 clinical guideline source

Readers on

mendeley: 124 Mendeley

So far, Altmetric has seen 18 news stories from 13 outlets.

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

BioSpace, 12 Oct 2026

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular…

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

ValueSpectrum, 10 Oct 2026

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular…

News story from Finanz Nachrichten on Saturday 10 October 2026

Finanz Nachrichten, 10 Oct 2026

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

The Manila Times, 10 Oct 2026

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 14 additional news stories.